1.75
price down icon44.79%   -1.42
after-market After Hours: 1.75
loading
Iovance Biotherapeutics Inc stock is traded at $1.75, with a volume of 111.99M. It is down -44.79% in the last 24 hours and down -46.48% over the past month. Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
See More
Previous Close:
$3.17
Open:
$1.94
24h Volume:
111.99M
Relative Volume:
9.94
Market Cap:
$1.17B
Revenue:
$32.77M
Net Income/Loss:
$-440.22M
P/E Ratio:
-1.0479
EPS:
-1.67
Net Cash Flow:
$-400.48M
1W Performance:
-50.00%
1M Performance:
-46.48%
6M Performance:
-83.47%
1Y Performance:
-86.99%
1-Day Range:
Value
$1.65
$1.985
1-Week Range:
Value
$1.65
$3.73
52-Week Range:
Value
$1.65
$13.20

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Name
Name
Iovance Biotherapeutics Inc
Name
Phone
(650) 260-7120
Name
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Name
Employee
838
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
IOVA's Discussions on Twitter

Compare IOVA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IOVA
Iovance Biotherapeutics Inc
1.75 1.17B 32.77M -440.22M -400.48M -1.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
424.99 128.84B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
527.78 65.38B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
549.65 39.67B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.15 33.82B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
231.99 27.60B 3.81B -644.79M -669.77M -6.24

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Date Action Analyst Rating Change
May-09-25 Downgrade Citizens JMP Mkt Outperform → Mkt Perform
Oct-24-24 Initiated UBS Buy
Jul-29-24 Downgrade Piper Sandler Overweight → Neutral
Nov-20-23 Initiated Goldman Buy
Sep-18-23 Reiterated Barclays Overweight
May-30-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-27-23 Resumed Wells Fargo Equal Weight
Jan-27-23 Upgrade Piper Sandler Neutral → Overweight
Dec-09-22 Downgrade Goldman Buy → Neutral
Oct-31-22 Initiated Guggenheim Neutral
Aug-18-22 Resumed Wells Fargo Equal Weight
Jan-28-22 Upgrade Stifel Hold → Buy
Dec-07-21 Resumed Cowen Outperform
Jun-10-21 Upgrade JMP Securities Mkt Perform → Mkt Outperform
May-20-21 Downgrade Piper Sandler Overweight → Neutral
May-19-21 Downgrade JMP Securities Mkt Outperform → Mkt Perform
May-19-21 Downgrade Stifel Buy → Hold
May-03-21 Initiated Truist Buy
Apr-16-21 Initiated Goldman Buy
Mar-08-21 Upgrade H.C. Wainwright Neutral → Buy
Dec-15-20 Downgrade H.C. Wainwright Buy → Neutral
Oct-06-20 Downgrade Wells Fargo Overweight → Equal Weight
Apr-22-20 Initiated Mizuho Buy
Mar-04-20 Initiated Barclays Overweight
Feb-26-20 Reiterated H.C. Wainwright Buy
Feb-26-20 Reiterated Oppenheimer Outperform
Dec-18-19 Initiated JMP Securities Mkt Outperform
Oct-01-19 Initiated Stifel Buy
Apr-29-19 Initiated Piper Jaffray Overweight
Feb-28-19 Reiterated Chardan Capital Markets Buy
Feb-07-19 Initiated Robert W. Baird Outperform
Dec-31-18 Resumed B. Riley FBR Buy
Jul-06-18 Reiterated Chardan Capital Markets Buy
Apr-10-18 Upgrade B. Riley FBR, Inc. Neutral → Buy
Mar-13-18 Reiterated B. Riley FBR, Inc. Neutral
Feb-23-18 Downgrade B. Riley FBR, Inc. Buy → Neutral
Jan-25-18 Reiterated H.C. Wainwright Buy
Nov-01-17 Reiterated B. Riley FBR, Inc. Buy
View All

Iovance Biotherapeutics Inc Stock (IOVA) Latest News

pulisher
09:55 AM

Market Today: Trade Desk Surges on Strong Earnings; Iovance Biotherapeutics Plummets - GuruFocus

09:55 AM
pulisher
04:53 AM

Iovance Biotherapeutics (IOVA) Downgraded by JMP Securities | IO - GuruFocus

04:53 AM
pulisher
03:41 AM

Iovance Biotherapeutics (IOVA) Stock Rating Maintained, Price Ta - GuruFocus

03:41 AM
pulisher
May 09, 2025

JMP Securities Downgrades Iovance Biotherapeutics (LSE:0JDK) - Nasdaq

May 09, 2025
pulisher
May 09, 2025

Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - Business Wire

May 09, 2025
pulisher
May 09, 2025

Securities Fraud Investigation Into Iovance Biotherapeutics, Inc. (IOVA) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Business Wire

May 09, 2025
pulisher
May 09, 2025

Iovance Biotherapeutics (IOVA) Shares Plummet on Revenue Miss an - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi - Endpoints News

May 09, 2025
pulisher
May 09, 2025

Iovance Biotherapeutics (IOVA) Shares Plummet on Revenue Miss and Forecast Cut - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Iovance falls after guidance cut, revenue miss - MSN

May 09, 2025
pulisher
May 09, 2025

Iovance stock falls after guidance cut, Q1 miss (IOVA:NASDAQ) - Seeking Alpha

May 09, 2025
pulisher
May 09, 2025

Why Iovance Biotherapeutics Stock Is Crashing Today - AOL.com

May 09, 2025
pulisher
May 09, 2025

Iovance Biotherapeutics (IOVA) Downgraded by JMP Securities | IOVA Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Iovance Stock Sinks 46%. Here’s Why the Biotech Is Tumbling. - Barron's

May 09, 2025
pulisher
May 09, 2025

Why Iovance (IOVA) Stock Is Plummeting Today - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Iovance Biotherapeutics (IOVA) Price Target Cut by TD Cowen | IOVA Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Expert Outlook: Iovance Biotherapeutics Through The Eyes Of 9 Analysts - Benzinga

May 09, 2025
pulisher
May 09, 2025

Iovance Biotherapeutics (IOVA) Downgraded Amid Concerns Over Lau - GuruFocus

May 09, 2025
pulisher
May 09, 2025

No Excuses, Iovance Biotherapeutics' Amtagvi Launch Has Underperformed (NASDAQ:IOVA) - Seeking Alpha

May 09, 2025
pulisher
May 09, 2025

Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% On '25 View Cut - Barchart.com

May 09, 2025
pulisher
May 09, 2025

Sector Update: Health Care - marketscreener.com

May 09, 2025
pulisher
May 09, 2025

Baird Downgrades Iovance Biotherapeutics to Neutral From Outperform, Adjusts Price Target to $3 From $20 - marketscreener.com

May 09, 2025
pulisher
May 09, 2025

Iovance Biotherapeutics (IOVA) Price Target Cut Following Revised Revenue Outlook | IOVA Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut - Zacks Investment Research

May 09, 2025
pulisher
May 09, 2025

Iovance Biotherapeutics (IOVA) Price Target Lowered by HC Wainwright | IOVA Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Iovance Biotherapeutics (IOVA) Target Price Reduced but Buy Rating Maintained | IOVA Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Iovance Biotherapeutics: Q1 Earnings Snapshot - New Haven Register

May 09, 2025
pulisher
May 09, 2025

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025 - GlobeNewswire

May 09, 2025
pulisher
May 09, 2025

Iovance Biotherapeutics Q1 Loss Narrows, Revenue Rises - marketscreener.com

May 09, 2025
pulisher
May 09, 2025

Iovance Biotherapeutics Reports Q1 2025 Financial Results - TipRanks

May 09, 2025
pulisher
May 09, 2025

Iovance Biotherapeutics Inc (IOVA) Q1 2025 Earnings Call Highlights: Strong Revenue from Antagy ... - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Decoding Iovance Biotherapeutics Inc (IOVA): A Strategic SWOT Insight - GuruFocus

May 09, 2025
pulisher
May 09, 2025

(IOVA) Technical Data - news.stocktradersdaily.com

May 09, 2025
pulisher
May 08, 2025

Iovance Biotherapeutics (IOVA) Projects Revenue Growth and Expanded Market Reach - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Iovance Biotherapeutics: Buy Rating Amid Signs of Recovery and Growth Potential - TipRanks

May 08, 2025
pulisher
May 08, 2025

Iovance revises 2025 revenue guidance to $250M-$300M amid ATC expansion - MSN

May 08, 2025
pulisher
May 08, 2025

Iovance Biotherapeutics earnings missed by $0.12, revenue fell short of estimates - Investing.com Canada

May 08, 2025
pulisher
May 08, 2025

Earnings call transcript: Iovance Biotherapeutics misses Q1 2025 EPS forecasts, stock drops - Investing.com

May 08, 2025
pulisher
May 08, 2025

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

IOVANCE BIOTHERAPEUTICS, INC. SEC 10-Q Report - TradingView

May 08, 2025
pulisher
May 08, 2025

Iovance Biotherapeutics (IOVA) Q1 2025 Earnings Miss Estimates - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Iovance (IOVA) Misses Q1 Revenue Expectations, Projects Growth in Q2 | IOVA Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Iovance Biotherapeutics Inc Reports Q1 2025 Earnings: EPS Misses at -$0.36, Revenue Falls Short at $49.3 Million - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Iovance Biotherapeutics (IOVA) Sees Increased Options Activity A - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Earnings Flash (IOVA) Iovance Biotherapeutics Reports Q1 Revenue $49.3M, vs. FactSet Est of $82.4M - marketscreener.com

May 08, 2025
pulisher
May 07, 2025

Uncovering Potential: Iovance Biotherapeutics's Earnings Preview - Nasdaq

May 07, 2025
pulisher
May 07, 2025

Iovance Biotherapeutics (NasdaqGM:IOVA) Sees 3% Price Increase Over Last Month - Yahoo Finance

May 07, 2025
pulisher
May 06, 2025

Iovance Biotherapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView

May 06, 2025
pulisher
May 06, 2025

Iovance Biotherapeutics’ SWOT analysis: promising immunotherapy stock faces challenges - Investing.com

May 06, 2025
pulisher
May 06, 2025

My 3 Favorite Stocks to Buy Right Now - The Motley Fool

May 06, 2025
pulisher
May 06, 2025

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space - insights.citeline.com

May 06, 2025

Iovance Biotherapeutics Inc Stock (IOVA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$65.08
price down icon 0.84%
$19.36
price down icon 0.31%
$33.15
price up icon 0.15%
$23.96
price down icon 2.80%
$92.77
price down icon 2.12%
biotechnology ONC
$231.99
price down icon 1.67%
Cap:     |  Volume (24h):